Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- DLTH -11.3%, ALOG -9.5%, SIGM -7.3%, NAV -7%, AMBA -4.6%, (also authorized the repurchase of up to an additional $50 million of its ordinary shares over a twelve-month period commencing July 1, 2017), OXM -2.7%, PLAY -2.5%, (also adds $100 mln to repurchase ), UNFI -2.2%, USPH -1.1%
Other news:
- KMDA -7.9% (to assume ownership from Shire (SHPG) of the Investigational New Drug application approved by the FDA for the Phase 2/3 study evaluating Alpha-1 Antitrypsin)
- EXAS -4.1% (prices common stock public offering of 7 mln shares at $35/share)
- GBDC -2.1% (announces public offering of 1.75 mln shares of its common stock)
- SHPG -1.7% (KMDA to assume ownership from Shire of the Investigational New Drug application approved by the FDA for the Phase 2/3 study evaluating Alpha-1 Antitrypsin)
- VLRS -1.2% (May traffic)
- UPLD -1.1% (to offer and sell shares of its common stock)
- AZN -1.1% (to divest rights to Zomig outside of Japan for $200 mln)
Analyst comments:
- QHC -2.6% (initiated with an Underweight at Morgan Stanley)
- RCII -2.6% (downgraded to Sell from Hold at Loop Capital)
- IRM -2.3% (downgraded to Sell from Hold at Deutsche Bank)
- IMAX -1.4% (downgraded to Hold from Buy at The Benchmark Company)
- KO -0.8% (downgraded to Market Perform from Outperform at BMO Capital)
- PEP -0.7% (downgraded to Market Perform from Outperform at BMO Capital)
- CYH -0.5% (initiated with an Underweight at Morgan Stanley)